Vertex casually drops Orkambi revenue slowdown, creating

Cystic fibrosis drugmaker Vertex this week informally backed away from its revenue guidance for key med Orkambi--and investors should be just as unhappy with execs’ conduct as they should be about | Cystic fibrosis drugmaker Vertex this week informally backed away from its revenue guidance for key med Orkambi--and investors should be just as unhappy with execs’ conduct as they should be about the revenue slip, one analyst says.

Long Zoom, Short WeWork: An Outrageous Profitable Idea (NYSE:WE)

BART on X: Board Workshop started with Regional Context & Financial Outlook presented by staff followed by Board discussion. Downtown San Francisco has had the slowest recovery among peer Downtowns. BART ridership

Vertex Pharmaceuticals' Revenue by Product (2016-2023)

Vertex Reports First Quarter 2023 Financial Results

Vertex grows on back of Trikafta/Kaftrio sales

Zoom: 7.8% Free Cash Flow Yield And $6B In Cash, With No Debt (NASDAQ:ZM)

News on Wikipedia: New Zealand selects flags, Google freshens up, and more

SEC Filing – Royalty Pharma

SEC Filing – Royalty Pharma

Check out these new features and extensions kicked off at Google Summer of Code 2015

S-1

S-1

S-1

SEC Filing – Royalty Pharma

Inventory Analytics: Identify And Manage Slow-Moving & Obsolete Inventory